Print Page

给 医 护 专 业 人 员 的 信
 
BCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. BCMA  
Related Information:
Canada: Summary Safety Review - Breyanzi (lisocabtagene maraleucel), Carvykti (c... 上载于 2025-02-01
CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell o... 上载于 2024-06-17
European Union: CAR T-cell medicines: PRAC identifies risk of secondary malignan... 上载于 2024-06-15
The United States: FDA Requires Boxed Warning for T cell Malignancies Following ... 上载于 2024-04-19
The United States: BCMA- and CD19-directed genetically modified autologous chime... 上载于 2024-01-24
European Union: Start of safety review of CAR T-cell medicines (English only) 上载于 2024-01-15
The United States: FDA investigating serious risk of T-cell malignancy following... 上载于 2023-11-29
 
back